Oncternal Therapeutics Stock Market Value
| ONCT Stock | USD 1.11 0.05 4.31% |
| Symbol | Oncternal |
Oncternal Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.69) | Revenue Per Share 0.73 | Quarterly Revenue Growth 1.76 | Return On Assets (0.76) | Return On Equity (1.50) |
The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oncternal Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oncternal Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oncternal Therapeutics.
| 10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in Oncternal Therapeutics on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding Oncternal Therapeutics or generate 0.0% return on investment in Oncternal Therapeutics over 30 days. Oncternal Therapeutics is related to or competes with Lyra Therapeutics, Hookipa Pharma, SAB Biotherapeutics, Cadrenal Therapeutics,, Monopar Therapeutics, Spero Therapeutics, and Coherus BioSciences. Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapi... More
Oncternal Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oncternal Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oncternal Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 65.49 | |||
| Value At Risk | (14.12) | |||
| Potential Upside | 11.49 |
Oncternal Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncternal Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oncternal Therapeutics' standard deviation. In reality, there are many statistical measures that can use Oncternal Therapeutics historical prices to predict the future Oncternal Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (1.28) | |||
| Total Risk Alpha | (2.81) | |||
| Treynor Ratio | 2.18 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Oncternal Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Oncternal Therapeutics Backtested Returns
Oncternal Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.11, which implies the firm had a -0.11% return per unit of risk over the last 3 months. Oncternal Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Oncternal Therapeutics' Coefficient Of Variation of (848.80), variance of 127.5, and Risk Adjusted Performance of (0.08) to confirm the risk estimate we provide. The company holds a Beta of -0.62, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Oncternal Therapeutics are expected to decrease at a much lower rate. During the bear market, Oncternal Therapeutics is likely to outperform the market. At this point, Oncternal Therapeutics has a negative expected return of -1.26%. Please make sure to check Oncternal Therapeutics' treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Oncternal Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.39 |
Below average predictability
Oncternal Therapeutics has below average predictability. Overlapping area represents the amount of predictability between Oncternal Therapeutics time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oncternal Therapeutics price movement. The serial correlation of 0.39 indicates that just about 39.0% of current Oncternal Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.39 | |
| Spearman Rank Test | 0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Oncternal Therapeutics lagged returns against current returns
Autocorrelation, which is Oncternal Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Oncternal Therapeutics' stock expected returns. We can calculate the autocorrelation of Oncternal Therapeutics returns to help us make a trade decision. For example, suppose you find that Oncternal Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Oncternal Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Oncternal Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Oncternal Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Oncternal Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Oncternal Therapeutics Lagged Returns
When evaluating Oncternal Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Oncternal Therapeutics stock have on its future price. Oncternal Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Oncternal Therapeutics autocorrelation shows the relationship between Oncternal Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Oncternal Therapeutics.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.